Liprin-α1 Contributes to Oncogenic MAPK Signaling by Counteracting ERK Activity

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2024 Jan 24

PMID 38264964

Authors

Henna Pehkonen

Artemis Filippou

Juho Vaananen

Iida Lindfors

Mira Vanttinen

Philipp Ianevski

Anne Makela

Pauliina Munne

Juha Klefstrom

Sanna Toppila-Salmi

Reidar Grenman

Jaana Hagstrom

Antti A Makitie

Piia-Riitta Karhemo

Outi Monni

Affiliations

Soon will be listed here.

Abstract

PTPRF interacting protein alpha 1 (PPFIA1) encodes for liprin-α1, a member of the leukocyte common antigen-related protein tyrosine phosphatase (LAR-RPTPs)-interacting protein family. Liprin-α1 localizes to adhesive and invasive structures in the periphery of cancer cells, where it modulates migration and invasion in head and neck squamous cell carcinoma (HNSCC) and breast cancer. To study the possible role of liprin-α1 in anticancer drug responses, we screened a library of oncology compounds in cell lines with high endogenous PPFIA1 expression. The compounds with the highest differential responses between high PPFIA1-expressing and silenced cells across cell lines were inhibitors targeting mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinases (ERK) signaling. KRAS proto-oncogene, GTPase (KRAS)-mutated MDA-MB-231 cells were more resistant to trametinib upon PPFIA1 knockdown compared with control cells. In contrast, liprin-α1-depleted HNSCC cells with low RAS activity showed a context-dependent response to MEK/ERK inhibitors. Importantly, we showed that liprin-α1 depletion leads to increased p-ERK1/2 levels in all our studied cell lines independent of KRAS mutational status, suggesting a role of liprin-α1 in the regulation of MAPK oncogenic signaling. Furthermore, liprin-α1 depletion led to more pronounced redistribution of RAS proteins to the cell membrane. Our data suggest that liprin-α1 is an important contributor to oncogenic RAS/MAPK signaling, and the status of liprin-α1 may assist in predicting drug responses in cancer cells in a context-dependent manner.

References

Yin G, Zheng Q, Yan C, Berk B . GIT1 is a scaffold for ERK1/2 activation in focal adhesions. J Biol Chem. 2005; 280(30):27705-12. DOI: 10.1074/jbc.M502271200. View

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A . Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013; 3(12):1416-29. DOI: 10.1158/2159-8290.CD-13-0350. View

Pehkonen H, de Curtis I, Monni O . Liprins in oncogenic signaling and cancer cell adhesion. Oncogene. 2021; 40(46):6406-6416. PMC: 8602034. DOI: 10.1038/s41388-021-02048-1. View

Mendoza M, Er E, Zhang W, Ballif B, Elliott H, Danuser G . ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex. Mol Cell. 2011; 41(6):661-71. PMC: 3078620. DOI: 10.1016/j.molcel.2011.02.031. View

Asperti C, Pettinato E, de Curtis I . Liprin-alpha1 affects the distribution of low-affinity beta1 integrins and stabilizes their permanence at the cell surface. Exp Cell Res. 2010; 316(6):915-26. DOI: 10.1016/j.yexcr.2010.01.017. View

Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B . Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018; 11:7095-7107. PMC: 6200076. DOI: 10.2147/OTT.S182721. View

Pehkonen H, von Nandelstadh P, Karhemo P, Lepikhova T, Grenman R, Lehti K . Liprin-α1 is a regulator of vimentin intermediate filament network in the cancer cell adhesion machinery. Sci Rep. 2016; 6:24486. PMC: 4830931. DOI: 10.1038/srep24486. View

Liu W, Zhang X . KAI1/CD82, a tumor metastasis suppressor. Cancer Lett. 2005; 240(2):183-94. DOI: 10.1016/j.canlet.2005.08.018. View

Astro V, Chiaretti S, Magistrati E, Fivaz M, de Curtis I . Liprin-α1, ERC1 and LL5 define polarized and dynamic structures that are implicated in cell migration. J Cell Sci. 2014; 127(Pt 17):3862-76. DOI: 10.1242/jcs.155663. View

10.

Serra-Pages C, Kedersha N, Fazikas L, Medley Q, Debant A, Streuli M . The LAR transmembrane protein tyrosine phosphatase and a coiled-coil LAR-interacting protein co-localize at focal adhesions. EMBO J. 1995; 14(12):2827-38. PMC: 398401. DOI: 10.1002/j.1460-2075.1995.tb07282.x. View

11.

de Curtis I . Biomolecular Condensates at the Front: Cell Migration Meets Phase Separation. Trends Cell Biol. 2021; 31(3):145-148. DOI: 10.1016/j.tcb.2020.12.002. View

12.

Mana G, Clapero F, Panieri E, Panero V, Bottcher R, Tseng H . PPFIA1 drives active α5β1 integrin recycling and controls fibronectin fibrillogenesis and vascular morphogenesis. Nat Commun. 2016; 7:13546. PMC: 5122980. DOI: 10.1038/ncomms13546. View

13.

Meredith S, Levine P, Burns J, Gaffey M, Boyd J, Weiss L . Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg. 1995; 121(7):790-4. DOI: 10.1001/archotol.1995.01890070076016. View

14.

Asperti C, Astro V, Totaro A, Paris S, de Curtis I . Liprin-alpha1 promotes cell spreading on the extracellular matrix by affecting the distribution of activated integrins. J Cell Sci. 2009; 122(Pt 18):3225-32. DOI: 10.1242/jcs.054155. View

15.

Shen J, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K . Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res. 2007; 67(6):2552-8. PMC: 2569966. DOI: 10.1158/0008-5472.CAN-06-3870. View

16.

Huang X, Gollin S, Raja S, Godfrey T . High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A. 2002; 99(17):11369-74. PMC: 123263. DOI: 10.1073/pnas.172285799. View

17.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

18.

Jarvinen A, Autio R, Haapa-Paananen S, Wolf M, Saarela M, Grenman R . Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. Oncogene. 2006; 25(52):6997-7008. DOI: 10.1038/sj.onc.1209690. View

19.

Ormandy C, Musgrove E, Hui R, Daly R, Sutherland R . Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003; 78(3):323-35. DOI: 10.1023/a:1023033708204. View

20.

Hancock J, Parton R . Ras plasma membrane signalling platforms. Biochem J. 2005; 389(Pt 1):1-11. PMC: 1184533. DOI: 10.1042/BJ20050231. View